Citalopram-induced photopigmentation

Journal of Dermatology

Volumn 28, Issue 12, 2001, Pages 742-745

  I˚nalöz, H Serhat ^a   Kirtak, Necmettin ^a   Herken, Hasan ^a   Özgöztaşi, Orhan ^a   Aynacioğlu, A Şükrü ^b  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

Adverse event; Citalopram; Photopigmentation

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DIAZEPAM; MEPHENYTOIN; MOCLOBEMIDE; OMEPRAZOLE; PROGUANIL; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DEPRESSION; DRUG INDUCED DISEASE; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; HUMAN; HYPERPIGMENTATION; SKIN MANIFESTATION; TREATMENT OUTCOME;

CITALOPRAM; DEPRESSION; DIAGNOSIS, DIFFERENTIAL; FACE; FEMALE; FOREARM; HUMANS; HYPERPIGMENTATION; MIDDLE AGED; NECK; PHOTOSENSITIVITY DISORDERS; SEROTONIN UPTAKE INHIBITORS;

EID: 0035677330     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2001.tb00070.x     Document Type: Article

References (22)

1. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression
2. Pharmacokinetics of selective serotonin reuptake inhibitors
3. Citalopram in the treatment of depression and other potential uses in psychiatry
4. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?
5. The major genetic defect responsible for S-mephenytoin metabolism in humans
6. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
7. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population
8. Steroselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation
9. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele
10. A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
11. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians
12. Identification of new human CYP2C19 alleles (C5T2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin
13. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin
14. SSRIs and unusual side effects
15. SSRI safety in overdose
16. Seizures and myoclonus associated with antidepressant treatment: Assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors
17. Ultrastructural and X-ray microanalytical observations of minocycline-related hyperpigmentation of the skin
18. Desipramine-induced blue-gray photosensitive pigmentation
19. Photosensitivity reaction to fluoxetine and alprazolam
20. Photosensitivity reaction to fluoxetine
21. Movement disorders associated with the serotonin selective reuptake inhibitors
22. Selective serotonin reuptake inhibitor discontinuation syndrome: Proposed diagnostic criteria